rate ratios (RR±1SE) were from logrank analyses by allocated treatment. 8
Introduction 1
In the trials of about 5 years of adjuvant tamoxifen vs no tamoxifen for early breast cancer, 2 follow-up now extends well into the second decade since randomisation. This allows better 3 assessment of long-term effects on breast cancer mortality and other mortality, and of the 4 effects of endocrine therapy in disease that is only weakly hormone-receptor-positive. We 5 report updated meta-analyses of data on each individual woman in these trials, relating the 6 effects of tamoxifen to quantitative measurements of hormone receptor levels, use of 7 chemotherapy and other factors. 8 9
Methods

10
Trial identification and data handling procedures have been described previously.
1- 3 We 11 sought updated data from each randomised trial in early breast cancer of adjuvant 12
tamoxifen vs not where only tamoxifen differed (ie, unconfounded trials). DCIS trials are 13 excluded. Results on only 1-2 years of adjuvant tamoxifen (n=33,000 women randomised) 14 are essentially unchanged since previously reported, 1 and are given only in the 15 webappendix. We report here the trials of longer tamoxifen durations (described as about 16 5 years of tamoxifen: n=21,457). Most [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] (n=12,551) were of exactly 5 years of tamoxifen, 17 four [16] [17] [18] [19] [20] (n=2750) were of only 3 years, one 21 (n=2196) re-randomised some at year 2 to 18 with ER [if ER≥10] p=0.002). In ER+ disease, the PR measurements were not predictive of 1 who would respond to tamoxifen, so subsequent analyses ignore PR and are limited to the 2 10,645 women with ER+ disease, with median follow-up in survivors 13 (IQR9-18) years. 3
4
The 10-year recurrence risks for women with node-negative and node-positive ER+ 5 disease are illustrated in figure 3 , subdivided by use of chemotherapy. Even if 6 chemotherapy was given (lower panels), tamoxifen was of substantial further benefit (ie, 7 chemotherapy plus tamoxifen was better than chemotherapy alone), producing a further 8 reduction of about one-quarter in 10-year recurrence risk (from 25% down to 18% in N-9 disease and 48% down to 36% in N+ disease). (except the period 10+ years after entry). Corresponding subgroup analyses for breast 18 cancer mortality (ie, mortality rate in all women less that in women without recurrence) 19 yield generally similar findings (webappendix, p4), except that a substantial mortality 20 reduction continued well beyond year 10 (RR during years 10+ after entry=0.73±0.07, 21 p<0.00001). Thus, the recurrence reduction during years 0-9 caused a highly significant 22 reduction in breast cancer mortality both during and after years 0-9. 23
24
The recurrence reduction appeared somewhat greater in trials of higher daily doses 25 (p=0.02 for trend between RRs for 20, 30 and 40 mg/day), but there was no such dose 26 effect for breast cancer mortality (webappendix, p4) or endometrial cancer incidence (data 27 not shown). There were highly significant effects both in the 6 trials with no chemotherapy 28 (RR=0.56±0.04) and in the 14 trials of chemotherapy plus tamoxifen vs the same 29 chemotherapy alone (RR=0.67±0.04), with -in both trial categories -a slightly greater 30 effect of tamoxifen in those with greater degrees of ER positivity (data not shown). For 31 patients receiving chemotherapy, tamoxifen was of further benefit whether it started 32 concurrently with the chemotherapy (RR=0.62±0.06) or after it (RR=0.71±0.05). The slight 33 superiority of starting concurrently is, however, not significant, and these tamoxifen trials
1
The proportional risk reductions were slightly, but not significantly, greater at older ages, 2 but benefits were substantial and consistent for women in each age range (including the 3 many with entry age <45 years [and the few with entry age 70+ years: 41/146 vs 68/156 4 recurrences/patients, 2p=0.001]). Nodal status, tumour grade and diameter did not 5 materially affect proportional risk reductions. They were, however, importantly predictive of 6 the absolute risk without tamoxifen, and hence of the absolute benefit of giving tamoxifen. 7
Local recurrence, contralateral breast cancer (generally new primary) and distant 8 recurrence were all substantially reduced by tamoxifen (each p<0.00001). 9
10
The proportional effects on recurrence rates were very different during different time 11 periods: figure 4(i). Recurrence was reduced by more than half during the first 2 years 12 (when almost all those allocated treatment would have been partially or fully treated) and 13 by almost half during the next 3 years. During years 5-9 after randomisation there was (in 14 all but two trials 23, 25 ) no difference in adjuvant tamoxifen usage between the treatment and 15 control groups, yet the recurrence rate was still almost one-third lower in those originally 16 allocated tamoxifen (RR=0.68±0.06, p<0.0001). After year 10, recurrence rates were 17 similar (RR=0.97±0.10), indicating no loss after year 10 of the gains during years 0-9. by which time trial treatment had ended (in all except the few re-randomised to continue 26 after year 5), but it was three times as great (24% vs 33%) by year 15. 27
28
In ER+ disease, the reductions in recurrence and mortality during years 0-4 were almost 29 as great in trials of only 1-2 years as in trials of about 5 years of tamoxifen (webappendix 30 p2, pp18-23). The reductions in recurrence during years 5-9 were, however, greater in the 31 trials of about 5 years of tamoxifen than in trials of only 1-2 years of tamoxifen. Although 1-32 Table 1 shows, for women with ER+ disease, effects on cause-specific mortality and on 1 second cancer incidence before any recurrence of the original breast cancer. (Effects on 2 diseases other than breast cancer were not materially affected by ER status: 3 webappendix, pp11-17.) As tamoxifen delayed or prevented recurrence, the tamoxifen 4 groups spent longer than controls at risk of death without recurrence (56,747 vs 48,876 5 woman-years). Hence, absolute numbers of deaths before recurrence in treatment and 6 control groups are not directly comparable, but logrank analyses account for this. 7
8
The main life-threatening side-effects of tamoxifen are uterine cancer and thromboembolic 9 disease.
1,26 In ER+ disease (mean 10 years follow-up) there were 9 vs 1 deaths from 10 uterine cancer (excluding cervix) and 6 vs 0 deaths from pulmonary embolus during the 11 first 5 years (but no apparent excess afterwards), suggesting about 0.2% 10-year mortality 12 from these two side-effects. Otherwise, there were no definite differences in mortality 13 without recurrence. A non-significant excess of stroke deaths -3 extra per 1000 women 14 during the first 15 years, none of it during the treatment period -was balanced by a non-15 significant shortfall in cardiac deaths -3 fewer per 1000 women during the first 15 years -16 so there was little net effect on overall vascular mortality (webappendix p14). 17
18
Tamoxifen increased uterine cancer incidence (excluding cervix cancer, RR=2.40±0.32, 19 p=0.00002), reduced contralateral breast cancer incidence by, in each age range, a larger 20 absolute amount and had no significant effect on other types of cancer (Table 1 and  21 webappendix pp16-17). These adverse and protective effects persisted for some years 22 after treatment ended (webappendix, pp 9-13). The uterine cancer risk was strongly 23 correlated with age, with little effect for entry age <45 or 45-54 years, but 15-year 24 incidence 3.8% vs 1.1% for entry age 55-69 years (absolute increase 2.6%, SE 0.6). In 25 contrast, the absolute (and proportional) decrease in contralateral breast cancer was 26 independent of age, with 15-year incidence 6.5% vs 9.8% in ER+ disease (absolute 27 reduction 3.2%, SE 0.8). In ER-poor disease the 15-year incidence of contralateral disease 28 was 7.1% in both treatment groups (absolute reduction 0.1%, SE 1.1). 29 
30
In the hypothetical absence of breast cancer mortality, 15-year probabilities of death from 31 other causes in these trials for entry ages <45, 45-54 and 55-69 years were, respectively, 32 3%, 6% and 20% (similar to population mortality rates). As this 20% risk for age 55-69 33 years applied similarly to the tamoxifen and to the control group, in both groups 15-year31/05/2011 is one-fifth smaller for overall mortality than for breast cancer mortality (Figure 6 ), but this 1 does not suggest any adverse effect on mortality from causes other than breast cancer. 2
For entry age <45 years, where intercurrent mortality was low, 15-year gains in overall 3 mortality and in breast cancer mortality were similar. 4
5
Discussion
6
Longer follow-up of the trials of about 5 years of tamoxifen has greatly strengthened the 7 evidence that substantially reduced breast cancer mortality rates continue well beyond 8 year 10, as a delayed effect of the greatly reduced recurrence rates during years 0-9. It 9 has also produced strong evidence of a substantial effect even in disease that was only 10 weakly ER-positive (10-19 fmol/mg), though not in disease that was wholly ER-negative. There appeared to be a fairly sharp cut-off in tamoxifen efficacy with respect to the 1 quantitative ER measurement between little effect at 4-9 fmol/mg and substantial benefit at 2 10-19 fmol/mg. (Reassuringly, ≥10 fmol/mg has been the criterion for ER positivity used in 3 most trials, and by the EBCTCG. 1 ) However, given the limitations of the ligand-binding ER 4 assay method used in these trials, 31 ,32 a sharp efficacy cut-off at a particular measurement 5 value is not plausible. Although the evidence of substantial benefit from tamoxifen at ER 6 levels of only 10-19 fmol/mg is robust, the evidence of zero benefit at 4-9 fmol/mg is not, 7
as the CI for tamoxifen efficacy just in this subgroup is wide, despite over 10,000 woman-8 years of follow-up. engender false negative claims about endocrine effects in some ER+ subgroup.
) 28 29
Given ER status, the PR measurement did not appear to be importantly predictive of 30 efficacy. In disease recorded as ER+ there was substantial and highly significant benefit 31 even if the sample was recorded as PR-poor. The absolute recurrence reduction at 15 32 years appeared if anything somewhat greater in ER+PR-poor than in ER+PR+ disease, 33 perhaps because of the somewhat higher background risk of recurrence without treatment.a subgroup with significant benefit. There did appear to be some slight early benefit from 1 tamoxifen in disease that was measured to be ER-poor, PR+ but this was not significant, 2 and might reflect inclusion in this category of a few patients with false-negative ER assays. 3
As assays improve, fewer breast cancers are reported as ER-PR+ (4% in the early 1990s 4 but only 1% in recent years in the SEER cancer registry data 30 ). For the few still reported 5 as ER-PR+, repeat testing on another tissue sample has been recommended 34, 36 to rule 6 out a false-negative ER assay in a patient who could benefit from endocrine treatment. 7
8
Although age is not a strong independent correlate of distant recurrence or of tamoxifen 9 efficacy, being relatively young is a major determinant of the gain in life expectancy from 10 avoiding distant recurrence. Moreover, for pre-or peri-menopausal women of age <45 or 11
45-54 years tamoxifen remains a major hormonal medical treatment option (as ovarian 12
activity cannot be controlled by aromatase inhibitors), and there is little uterine cancer risk 13 from giving tamoxifen at such ages. 14 
15
The key quantitative finding likely to be generalisable to future patients 37 is the proportional were approximately independent of any therapeutic effects of that chemotherapy (a 21 conclusion strongly reinforced by meta-analyses 1,39 of the trials of chemotherapy, which 22 found that the proportional risk reduction produced by chemotherapy was unaffected by 23 whether or not tamoxifen was being given). 24 
25
Insofar as any of these factors substantially affect absolute risk in women without 26 tamoxifen, they substantially affect the absolute reduction in risk produced by tamoxifen. 27
Many treatment guidelines recommend endocrine treatment for disease with any degree of 28 ER-positivity. 38 Consistently with this, the present meta-analyses show a definite and 29 substantial protective effect even at ER levels of only 10-19 fmol/mg, and demonstrate that 30 on average among all women with ER+ disease full compliance with 5 years of adjuvant 31 tamoxifen would reduce the breast cancer mortality rate during the first 15 years after the 32 start of treatment by at least a third, in comparison with no adjuvant endocrine therapy. Contributors The EBCTCG secretariat, including CD, JG, RG, MC, SD, PM, YW and RP, 7 identified trials, obtained datasets and had full access to them. JG, CD, RG, HP and RP 8 generated analyses and drafted the report with MD and JI as external advisors. All writing 9 committee members contributed to revising it. 10 11
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